System degeneration in an MM1-type sporadic Creutzfeldt-Jakob disease case with an unusually prolonged akinetic mutism state.
Creutzfeldt-Jakob disease
akinetic mutism state
panencephalopathic-type
pyramidal tract degeneration
system degeneration
Journal
Prion
ISSN: 1933-690X
Titre abrégé: Prion
Pays: United States
ID NLM: 101472305
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
entrez:
21
1
2021
pubmed:
22
1
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Methionine/methionine type 1 (MM1-type) sporadic Creutzfeldt-Jakob disease (sCJD), known as the 'classic type,' shows typical clinicopathological sCJD findings. In general, patients reach an akinetic mutism state within a few months of disease onset and die soon after if supportive therapies are not administered. Here, we describe remarkable neuropathologic observations of MM1-type sCJD in a 48-year-old, Japanese man with an unusually prolonged akinetic mutism state. In the early disease stages, the patient exhibited abnormal behaviour with gait disturbance and rapidly progressive cognitive dysfunction. Diffusion-weighted magnetic resonance imaging revealed extensive cerebral cortical hyperintensity. Prion protein (PrP) gene analysis revealed no mutations, and the polymorphic codon 129 exhibited methionine homozygosity. Although the patient remained stable with tube feeding for more than 2 years after reaching the akinetic mutism state, he died because of central respiratory failure 30 months after disease onset. Neuropathologic investigation showed extensive devastating lesions, such as status spongiosus, and typical spongiform changes could no longer be observed in the cerebral neocortex. Conspicuous pyramidal tract degeneration was observed. However, the regions commonly preserved in MM1-type sCJD pathology were still relatively preserved. Immunostaining revealed extensive diffuse synaptic-type PrP deposition in the grey matter. The pathological findings suggested that sCJD is a neurodegenerative disease that shows system degeneration; there are primary and secondary degenerative regions and distinct preserved regions, even in cases with prolonged disease duration. In addition, it is considered that there is a limited survival period for MM1-type sCJD, even if active symptomatic treatment is provided.
Identifiants
pubmed: 33472525
doi: 10.1080/19336896.2020.1868931
pmc: PMC7833778
doi:
Substances chimiques
Prion Proteins
0
Methionine
AE28F7PNPL
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12-20Références
Acta Neuropathol. 2005 Nov;110(5):490-500
pubmed: 16175355
Acta Neuropathol. 2005 Jun;109(6):557-66
pubmed: 15933870
Acta Neuropathol. 2006 Nov;112(5):561-71
pubmed: 16847689
J Neurol Neurosurg Psychiatry. 1981 Feb;44(2):103-15
pubmed: 7012278
J Neurol Sci. 2014 Jun 15;341(1-2):97-104
pubmed: 24787503
Brain Pathol. 1995 Oct;5(4):459-66
pubmed: 8974629
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neuropathology. 2008 Feb;28(1):51-61
pubmed: 18181835
Neuropathology. 2006 Dec;26(6):550-6
pubmed: 17203592
J Neurol Sci. 2015 Oct 15;357(1-2):63-8
pubmed: 26143527
Ann Neurol. 1999 Aug;46(2):224-33
pubmed: 10443888
Neuropathology. 2017 Apr;37(2):174-188
pubmed: 28028861
Acta Neuropathol. 2006 Oct;112(4):389-404
pubmed: 16906426
Prion. 2017 May 4;11(3):186-194
pubmed: 28509623
Acta Neuropathol Commun. 2013 Nov 13;1:74
pubmed: 24252157
Neuropathology. 2020 Oct;40(5):436-449
pubmed: 32363728
Neuropathology. 2017 Oct;37(5):420-425
pubmed: 28402042
Eur J Neurol. 2011 Jul;18(7):999-1002
pubmed: 20722706